✦ LIBER ✦

Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer

✍ Scribed by Han, Ji-Youn; Lim, Hyeong-Seok; Shin, Eun Soon; Yoo, Yeon-Kyeong; Park, Yong Hoon; Lee, Jong-Eun; Kim, Heung Tae; Lee, Jin Soo

Book ID: 119319727
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 207 KB
Volume: 59
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2007.07.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of Organic Anion-Transporting Pol

Effect of Organic Anion-Transporting Polypeptide 1B1 (OATP1B1) Polymorphism on the Single- and Multiple-Dose Pharmacokinetics of Enalapril in Healthy Chinese Adult Men

✍ Lei Tian; Hong Liu; Shuang Xie; Juanjuan Jiang; Lulu Han; Yiling Huang; Yishi Li 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 509 KB

Associations of ABCB1, ABCC2, and ABCG2

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer

✍ Ji-Youn Han; Hyeong-Seok Lim; Yeon-Kyeong Yoo; Eun Soon Shin; Yong Hoon Park; Su 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

## Abstract ## BACKGROUND. The authors investigated whether __ABCB1, ABCC2,__ and __ABCG2__ genetic polymorphisms affect pharmacokinetics (PK) of irinotecan and treatment outcome of patients with advanced nonsmall cell lung cancer (NSCLC). ## METHODS. Blood samples from 107 NSCLC patients treate

P063 Effect of Organic Anion-Transportin

P063 Effect of Organic Anion-Transporting Polypeptide 1B1 (OATP1B1) Polymorphism on the Single- and Multiple-Dose Pharmacokinetics of Enalapril in Healthy Chinese Adult Men

✍ L. Tian; H. Liu; S. Xie; J.J. Jiang; L.L. Han; Y.L. Huang; Y.S. Li 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Erratum: Associations of ABCB1, ABCC2, a

Erratum: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer

✍ Ji-Youn Han; Hyeong-Seok Lim; Yeon-Kyeong Yoo; Eun Soon Shin; Yong Hoon Park; Su 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views

Phase I/II Pharmacokinetic and Pharmacog

Phase I/II Pharmacokinetic and Pharmacogenomic Study of UGT1A1 Polymorphism in Elderly Patients With Advanced Non–Small Cell Lung Cancer Treated With Irinotecan

✍ Yamamoto, N; Takahashi, T; Kunikane, H; Masuda, N; Eguchi, K; Shibuya, M; Takeda 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 230 KB

Afatinib versus placebo for patients wit

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

✍ Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; San 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 373 KB